Recent large scale sequencing studies have delineated key molecular features associated with metastatic prostate cancer. Importantly, many of these alterations are forming the basis for emerging precision oncology strategies for these men. Specifically, mutations in genes involved in homologous recombination (HR) and mismatch repair (MMR) have been shown to predict for response to PARP inhibitors and immune checkpoint inhibitors, respectively. Additional alterations (e.g. PTEN and CDK12 aberrations) have also been proposed as candidate biomarkers for the selection of targeted therapies as well as immune checkpoint inhibitors.
The PROMISE Consortium is investigating prognostic and predictive biomarkers of response and resistance in patients with prostate cancer and evaluating for correlations between genomics data and clinical outcomes. The study will involve the collection of clinicopathologic and molecular data through review of medical charts/electronic records. All data will be retrospective in nature and no direct patient contact will be involved.
Clinical and Genomic Data
Abstracts and Publications
- The PROMISE Consortium: Filling Genomic Knowledge Gaps through Team Science, 27th Annual PCF Scientific Retreat Virtual Poster Session, October 2020.
- Administrative Headquarters - Maintains RedCap database and manages development of the consortium.
- Bioinformatics Committee - Formats somatic and germline alterations to standardized criteria and performs QC of genomic data.
- Executive Committee - Selects project proposals through scientific review.
- Data Committee - Independently performs approved analyses.
- Imaging/Radionucleotides Subcommittee
- Patient Advocacy and Diversity Subcommittee
- Therapeutics Subcommittee
- Biomarkers Subcommittee
- Outreach Subcommittee
- Publications Subcommittee